IMPACT STUDY

Recruiting to June 2022

Aim: This study aims to evaluate the effect of IMCY-0098 on the immune signature (treatment-specific biomarkers), and the effect of the study drug upon the preservation of beta-cell function in   adult patients with Type 1 Diabetes. Further safety data will also be collected.

What will taking part involve?

  • Going to one of the study locations eleven times over the course of a year, including screening and randomisation visits.
  • The main study (for patients who are HLA DR4 positive) will include receiving a dose of either the treatment being studied, or a placebo every two weeks, from randomisation to week 10, six times in total.
  • The sub-study (for patients who are HLA DR4 negative, but HLA DR3 positive) will include receiving a dose of the treatment being studied, every 2 weeks from randomisation to week 10, six times in total.
  • For both the main study and sub-study, a ‘booster’ dose of the same treatment will be given 24 weeks after the first treatment.

Contact the study directly:

Email: T1D Consortium


DIABETIC TWIN STUDY

Currently Recruiting

Aim: To study the influence of environment and genes on the onset of type 1 diabetes using identical twins.

What will taking part involve?

You will be asked to give a blood sample and a mouth swab sample, and you will be asked about your health

Contact the study directly:

Call: 020 7882 2365 Dr Mohammed Hawa, Study Manager
Email: m.i.hawa@qmul.ac.uk



Ver-A-T1D STUDY

Recruiting to November 2022

Aim: Verapamil, a known blood pressure lowering drug, has been shown recently to protect and strengthen beta cells and slows down beta cell destruction in Type 1 diabetes. The aim is to confirm the effect of 360mg Verapamil sustained release (SR) administered orally once daily (titrated over the first 3 months from 120 mg to 360 mg).

What will taking part involve?

  • Those who take part will be asked to attend a study visit for screening, then take a tablet once a day for 1 year which will either be Verapamil or a placebo.
  • There will be seven treatment visits and three phone visits during this time with different tests taken, and an optional follow up visit at 2 years.

Contact the study directly:

Email: T1D Consortium


DROPLeT STUDY

Recruiting to December 2021

Aim: The aim of this research is to find out if older adults (aged over 30) with Type 1 diabetes have similar rates of progression to young adults (aged under 30).

What will taking part involve?

  • The study can be completed entirely from home, with the equipment sent to you and samples returned by post.
  • On 3 occasions you will be asked to fast overnight and collect blood samples before and after a liquid meal, and you will be asked to wear a Continuous Glucose Monitor for the year and optionally provide weekly fingerprick blood samples.

Contact the study directly:

Call 01392 408184 or email:  rde-tr.DiabetesResearch@nhs.net


INNODIA

An innovative approach towards understanding and arresting type 1 diabetes

Recruiting

Summary
Europe-wide study collecting blood samples and data from people newly diagnosed with type 1 diabetes and first degree relatives, aged 1-45 years.

Aim
To develop a European infrastructure for the recruitment of newly diagnosed patients with type 1 diabetes (T1D) and unaffected family members, generating an unrivaled Bioresource for T1D discovery science.

Contact the study directly:

Contact us

Call: 01223 768616
Email: INNODIA-recruit@paed.cam.ac.uk
Website